The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Trends in overall survival and costs of multiple myeloma, 2000–2014
Open accessAbstract
Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive 2 years than those diagnosed in 2006. MM patients showed improved survival over the study period, with the 2-year survival gap between MM patients and matched controls decreasing at a rate of 3% per year. Total costs among MM patients have increased in all healthcare services over the years; however, the relative contribution of drug costs has remained fairly stable since 2009 despite new novel therapies coming to market. Findings from this study corroborate clinical data, suggesting a paradigm shift in MM treatment over the past decade that is associated with substantial survival gains. Future studies should focus on the impact on specific novel agents on patients' outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Porter, M. E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1011024 · Cited by 5,084
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationKumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Kyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 855
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 433
Self-citationAutologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Harousseau, J.-L., & Moreau, P. (2009) · New England Journal of Medicine · doi:10.1056/nejmct0805626 · Cited by 186
Outcome disparities in multiple myeloma: a SEER ‐based comparative analysis of ethnic subgroups
Ailawadhi, S., Aldoss, I. T., Yang, D., Razavi, P., Cozen, W., Sher, T., & Chanan-Khan, A. A. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09124.x · Cited by 124
Warren, J. L., Harlan, L. C., Stevens, J. L., Little, R. F., & Abel, G. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3323 · Cited by 101
Song, X., Cong, Z., & Wilson, K. L. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1105202 · Cited by 83
Teitelbaum, A. H., Ba-Mancini, A., Huang, H., & Henk, H. J. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0113 · Cited by 74
Garrison, L. P., Wang, S.-T., Huang, H., Ba-Mancini, A., Shi, H., Chen, K. S., Korves, C., Dhawan, R., Cakana, A., de Velde, H. J. V., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2011-0380 · Cited by 59
How should we treat newly diagnosed multiple myeloma patients?
Mateos, M., & Miguel, J. F. S. (2013) · Hematology · doi:10.1182/asheducation-2013.1.488 · Cited by 46
Ramsey, S. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9805 · Cited by 30
Willenbacher, E., Weger, R., Rochau, U., Siebert, U., Willenbacher, W., & Austrian Myeloma Registry (AMR) (2016) · PLoS ONE · doi:10.1371/journal.pone.0147381 · Cited by 18
Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia
Lin, P., Winn, A. N., Parsons, S. K., Neumann, P. J., Weiss, E. S., & Cohen, J. T. (2016) · Medical Care · doi:10.1097/mlr.0000000000000496 · Cited by 15
Five Myths About Cancer Care In America
Goldman, D. P., & Philipson, T. (2014) · Health Affairs · doi:10.1377/hlthaff.2014.0826 · Cited by 8
Cited by
Diagnosis and Management of Multiple Myeloma: A Review
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,029
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Metastatic bone disease: Pathogenesis and therapeutic options
D'Oronzo, S., Coleman, R., Brown, J., & Silvestris, F. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2018.10.004 · Cited by 255
Treatment options for triple-class refractory multiple myeloma.
Mikhael, J. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.621 · Cited by 126
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Metadata
- Authors
- Fonseca, R., Abouzaid, S., Bonafede, M., Cai, Q., Parikh, K., Cosler, L., & Richardson, P.
- Venue
- Leukemia
- Published
- 2016-12-23
- Volume
- 31
- Issue
- 9
- Pages
- 1915-1921
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2566193100
- Cited by
- 323
- References
- 18
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.